Patrick M ONeil
Overview
Explore the profile of Patrick M ONeil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schulte E, Tuerk P, Wadden T, Garvey W, Weiss D, Hermayer K, et al.
Int J Obes (Lond)
. 2020 Jan;
44(5):990-998.
PMID: 31949295
Background: A WW (formerly Weight Watchers) program adapted for persons with type 2 diabetes mellitus (T2DM) previously was found to be more effective than standard care (SC) intervention for weight...
12.
Boepple L, Cero I, Marek R, Coulon S, Lydecker J, Brown J, et al.
Obes Sci Pract
. 2020 Jan;
5(6):548-554.
PMID: 31890245
Objective: Research suggests that individuals seeking weight loss treatment do so for a variety of reasons. Limited work has explored relations of reasons for weight loss to patient characteristics or...
13.
Apovian C, Okemah J, ONeil P
Adv Ther
. 2018 Nov;
36(1):44-58.
PMID: 30465123
Obesity is one of the main risk factors for type 2 diabetes (T2D), representing a major worldwide health crisis. Modest weight-loss (≥ 5% but < 10%) can minimize and reduce...
14.
Hales S, Turner T, Sword D, Nance L, Brown J, ONeil P
J Occup Environ Med
. 2018 Sep;
60(12):1112-1115.
PMID: 30188492
Objective: The aim of the study was to assess weight loss outcomes among participants (N = 1090) of a weight management program across multiple worksites (N = 10) in a...
15.
ONeil P, Birkenfeld A, McGowan B, Mosenzon O, Pedersen S, Wharton S, et al.
Lancet
. 2018 Aug;
392(10148):637-649.
PMID: 30122305
Background: Obesity is a major public health issue, and new pharmaceuticals for weight management are needed. Therefore, we evaluated the efficacy and safety of the glucagon-like peptide-1 (GLP-1) analogue semaglutide...
16.
Brown J, Hales S, Evans T, Turner T, Sword D, ONeil P, et al.
J Telemed Telecare
. 2018 Jul;
26(1-2):28-35.
PMID: 30045661
Introduction: In the US, obesity rates are higher in rural areas than in urban areas. Rural access to treatment of obesity is limited by a lack of qualified clinicians and...
17.
Kaplan L, Golden A, Jinnett K, Kolotkin R, Kyle T, Look M, et al.
Obesity (Silver Spring)
. 2017 Nov;
26(1):61-69.
PMID: 29086529
Objective: ACTION (Awareness, Care, and Treatment in Obesity maNagement) examined obesity-related perceptions, attitudes, and behaviors among people with obesity (PwO), health care providers (HCPs), and employer representatives (ERs). Methods: A...
18.
Marek R, Coulon S, Brown J, Lydecker J, Marek S, Malcolm R, et al.
Obesity (Silver Spring)
. 2017 Nov;
25(12):2062-2067.
PMID: 29086487
Objective: Focusing on average weight loss (WL) from interventions provides useful efficacy data but masks large variability across patients. In this study, parameters of weight loss trajectories were determined that...
19.
ONeil P, Aroda V, Astrup A, Kushner R, Lau D, Wadden T, et al.
Diabetes Obes Metab
. 2017 Apr;
19(11):1529-1536.
PMID: 28386912
Aims: Liraglutide, a GLP-1 receptor agonist, regulates appetite via receptors in the brain. Because of concerns regarding the potential of centrally-acting anti-obesity medications to affect mental health, pooled neuropsychiatric safety...
20.
Holland-Carter L, Tuerk P, Wadden T, Fujioka K, Becker L, Miller-Kovach K, et al.
J Diabetes Complications
. 2017 Mar;
31(5):891-897.
PMID: 28319001
Aims: Type 2 diabetes mellitus (T2DM) can substantially decrease quality of life (QOL). This study examined the effects on QOL-relevant psychosocial measures of a widely available commercial weight loss program...